TY - JOUR
T1 - Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable
AU - Kefalakes, Helenie
AU - Jochum, Christoph
AU - Hilgard, Gudrun
AU - Kahraman, Alisan
AU - Bohrer, Anna Margarethe
AU - El Hindy, Nicolai
AU - Heinemann, Falko Markus
AU - Verheyen, Jens
AU - Gerken, Guido
AU - Roggendorf, Michael
AU - Timm, Joerg
N1 - Publisher Copyright:
© 2015 European Association for the Study of the Liver.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Background & Aims CD8+ T cells are an essential component of a successful immune response against hepatitis B virus (HBV). Patients who spontaneously clear HBsAg after acute HBV infection have a strong CD8+ T cell immune response, predominantly directed against the HBV core protein (HBcAg). However, the fate and phenotype of HBcAg-specific CD8+ T cells after immune control are unclear. Methods The CD8+ T cell immune response against HBV core was determined in 65 patients with chronic HBV infection, 16 patients after recovery from acute HBV infection, and four patients with acute HBV infection utilizing overlapping peptides and HLA class I/peptide-multimers. Results Patients who had cleared HBsAg >30 years ago had significantly weaker CD8+ T cell responses after antigen-specific expansion compared to patients who had cleared the virus <10 years ago and patients with HBeAg negative chronic infection and low viral load (<2000 IU/ml; p <0.01). Also directly ex vivo, patients who had cleared the HBsAg >30 years ago had less HBV-specific CD8+ T cells compared to patients with HBeAg negative chronic infection (p = 0.0025). In patients with acute HBV infection, the frequency of HBc-specific CD8+ T cells continued to decline after clearance of HBV-DNA and HBsAg even at a time when ALT levels had already normalized (p = 0.0313). Conclusions The frequency of HBcAg-specific CD8+ T cells continuously declines after HBsAg clearance. In line with clinical observations, this suggests that humoral and not CD8+ T cell immune responses mainly contribute to prevention of HBV reactivation decades after HBsAg clearance.
AB - Background & Aims CD8+ T cells are an essential component of a successful immune response against hepatitis B virus (HBV). Patients who spontaneously clear HBsAg after acute HBV infection have a strong CD8+ T cell immune response, predominantly directed against the HBV core protein (HBcAg). However, the fate and phenotype of HBcAg-specific CD8+ T cells after immune control are unclear. Methods The CD8+ T cell immune response against HBV core was determined in 65 patients with chronic HBV infection, 16 patients after recovery from acute HBV infection, and four patients with acute HBV infection utilizing overlapping peptides and HLA class I/peptide-multimers. Results Patients who had cleared HBsAg >30 years ago had significantly weaker CD8+ T cell responses after antigen-specific expansion compared to patients who had cleared the virus <10 years ago and patients with HBeAg negative chronic infection and low viral load (<2000 IU/ml; p <0.01). Also directly ex vivo, patients who had cleared the HBsAg >30 years ago had less HBV-specific CD8+ T cells compared to patients with HBeAg negative chronic infection (p = 0.0025). In patients with acute HBV infection, the frequency of HBc-specific CD8+ T cells continued to decline after clearance of HBV-DNA and HBsAg even at a time when ALT levels had already normalized (p = 0.0313). Conclusions The frequency of HBcAg-specific CD8+ T cells continuously declines after HBsAg clearance. In line with clinical observations, this suggests that humoral and not CD8+ T cell immune responses mainly contribute to prevention of HBV reactivation decades after HBsAg clearance.
KW - Anti-HBs
KW - CD8 T cell response
KW - HBV core
KW - HBcAg
KW - HBsAg
UR - http://www.scopus.com/inward/record.url?scp=84931567803&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2015.01.030
DO - 10.1016/j.jhep.2015.01.030
M3 - Article
C2 - 25646888
AN - SCOPUS:84931567803
SN - 0168-8278
VL - 63
SP - 13
EP - 19
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 1
M1 - 5533
ER -